These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 15599700

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-gamma coactivator-1 gene might be a risk factor for diabetic retinopathy in Slovene population (Caucasians) with type 2 diabetes and the Pro12Ala polymorphism of the PPARgamma gene is not.
    Petrovic MG, Kunej T, Peterlin B, Dovc P, Petrovic D.
    Diabetes Metab Res Rev; 2005; 21(5):470-4. PubMed ID: 15782399
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with hypertension in middle-aged men.
    Oberkofler H, Hölzl B, Esterbauer H, Xie M, Iglseder B, Krempler F, Paulweber B, Patsch W.
    Hypertension; 2003 Feb; 41(2):368-72. PubMed ID: 12574109
    [Abstract] [Full Text] [Related]

  • 10. PGC-1alpha Gly482Ser polymorphism is associated with the plasma adiponectin level in type 2 diabetic men.
    Okauchi Y, Iwahashi H, Okita K, Yuan M, Matsuda M, Tanaka T, Miyagawa J, Funahashi T, Horikawa Y, Shimomura I, Yamagata K.
    Endocr J; 2008 Dec; 55(6):991-7. PubMed ID: 18614852
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial.
    Andrulionytè L, Zacharova J, Chiasson JL, Laakso M, STOP-NIDDM Study Group.
    Diabetologia; 2004 Dec; 47(12):2176-84. PubMed ID: 15592662
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes.
    Barroso I, Luan J, Sandhu MS, Franks PW, Crowley V, Schafer AJ, O'Rahilly S, Wareham NJ.
    Diabetologia; 2006 Mar; 49(3):501-5. PubMed ID: 16435105
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of the peroxisome proliferator-activated receptor-gamma co-activator-1 Gly482Ser variant on features of the metabolic syndrome.
    Vohl MC, Houde A, Lebel S, Hould FS, Marceau P.
    Mol Genet Metab; 2005 Mar; 86(1-2):300-6. PubMed ID: 16122961
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Association between PGC-1alpha gene polymorphisms and type 2 diabetes risk: a case-control study of an Iranian population.
    Shokouhi S, Haghani K, Borji P, Bakhtiyari S.
    Can J Diabetes; 2015 Feb; 39(1):65-72. PubMed ID: 25282005
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.